Diurnal Group plc is a specialty pharmaceutical company that develops hormone therapeutics for the treatment of chronic endocrine conditions. Based in Cardiff, UK, the company's products aim to address conditions such as congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Diurnal Group's flagship products include Alkindi, a replacement therapy for paediatric adrenal insufficiency in Europe, and Chronocort, which has completed Phase III clinical trials for targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early stage pipeline includes Native Oral Testosterone, siRNA oligonucleotide therapy, and T3 modified hormone therapy.
Diurnal Group plc's ticker is DNL
The company's shares trade on the LSE stock exchange
They are based in Cardiff, Wales
There are 11-50 employees working at Diurnal Group plc
It is https://www.diurnal.com/
Diurnal Group plc is in the Healthcare sector
Diurnal Group plc is in the Drug Manufacturers - Other industry
The following five companies are Diurnal Group plc's industry peers: